Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Sees Large Drop in Short Interest

Posted by on Jul 30th, 2026

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN – Get Free Report) was the recipient of a large drop in short interest in July. As of July 15th, there was short interest totaling 920 shares, a drop of 39.0% from the June 30th total of 1,509 shares. Based on an average daily trading volume, of 1,787 shares, the short-interest ratio is currently 0.5 days. Currently, 0.1% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Addex Therapeutics in a report on Monday, July 6th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Check Out Our Latest Research Report on ADXN

Addex Therapeutics Price Performance

NASDAQ ADXN opened at $5.64 on Thursday. The stock’s 50 day simple moving average is $6.23 and its 200-day simple moving average is $6.79. The company has a market cap of $6.94 million, a PE ratio of -0.95 and a beta of 1.50. Addex Therapeutics has a 1-year low of $5.41 and a 1-year high of $12.05.

About Addex Therapeutics

(Get Free Report)

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.

Featured Stories

Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.